Sadeghi Bamdad, Abolhassani Hassan, Naseri Ali, Rezaei Nima, Aghamohammadi Asghar
Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Expert Rev Clin Immunol. 2015 May;11(5):681-8. doi: 10.1586/1744666X.2015.1029457. Epub 2015 Mar 25.
In the context of the unknown economic burden imposed by primary immunodeficiency diseases, in this study, we sought to calculate the costs associated with the most prevalent symptomatic disease, common variable immunodeficiency (CVID).
Direct, indirect and intangible costs were recorded for diagnosed CVID patients. Hidden Markov model was used to evaluate different disease-related factors and Monte Carlo method for estimation of uncertainty intervals.
The total estimated cost of diagnosed CVID is US$274,200/patient annually and early diagnosis of the disease can save US$6500. Hospital admission cost (US$25,000/patient) accounts for the most important expenditure parameter before diagnosis, but medication cost (US$40,600/patients) was the main factor after diagnosis primarily due to monthly administration of immunoglobulin.
The greatest cost-determining factor in our study was the cost of treatment, spent mostly on immunoglobulin replacement therapy of the patients. It was also observed that CVID patients' costs are reduced after diagnosis due to appropriate management.
在原发性免疫缺陷疾病所带来的未知经济负担背景下，本研究旨在计算与最常见的症状性疾病——普通可变免疫缺陷（CVID）相关的成本。
记录确诊的CVID患者的直接、间接和无形成本。使用隐马尔可夫模型评估不同的疾病相关因素，并采用蒙特卡罗方法估计不确定性区间。
确诊的CVID患者每年的总估计成本为274,200美元/患者，疾病的早期诊断可节省6500美元。住院费用（25,000美元/患者）在诊断前占最重要的支出参数，但药物费用（40,600美元/患者）在诊断后是主要因素，主要原因是每月进行免疫球蛋白治疗。
我们研究中最大的成本决定因素是治疗成本，主要用于患者的免疫球蛋白替代治疗。还观察到，由于适当的管理，CVID患者在诊断后的成本有所降低。
